Randox launches €99 Express COVID-19 Testing Service at Dublin Airport

Home - Diagnostics

Randox launches €99 Express COVID-19 Testing Service at Dublin Airport

Randox launches €99 Express COVID-19 Testing Service at Dublin Airport

16 November 2020: Randox launches 99 Express COVID-19 Testing Service at Dublin Airport

A 99 Express COVID-19 Testing Service which launches this week in a new Travel Testing Centre at Dublin Airport, will see the creation of 50 new jobs.

The testing service from Randox, a laboratory partner in the UK’s National COVID-19 Testing Programme, utilises a robust and reliable method of testing known as PCR, which Junior Minister for Transport Hildegarde Naughton described as “the gold standard” for travel testing.

The launch of the Randox Health Travel Centre, which offers rapid next day delivery of results for pre-departure screening as well as on-arrival testing to reduce quarantine timeframes, comes just after Ireland aligned itself with the new EU ‘traffic light’ system to co-ordinate international travel, on Sunday 8th November.

Sophie Boyd, Project Manager for the Randox Express COVID-19 Testing Service, explained;     

 “With the introduction of the new EU traffic lights system, some people will need a COVID-19 test before travelling or equally, will want a negative test result simply for their peace of mind.

“We are delighted to have secured a location at Dublin Airport, that allows us to extend our rapid and reliable COVID-19 Testing Service, already used by a range of well-known companies, airlines and elite sporting organisations, to individual passengers and consumers.”

The Irish Government has agreed that, whilst those arriving from red zones currently have to quarantine for 14 days, this could soon be waived following a negative result from a COVID-19 PCR test taken five days after arrival in Ireland.

Sophie continued;

“Travel requirements during the pandemic continue to evolve, but with the introduction of the EU traffic light system, a common prerequisite to travel or to shorten existing quarantine periods will be a negative PCR COVID-19 test, which is currently the only method of COVID-19 testing recognised and approved by every country worldwide.

“With significant capacity in place to implement high volume PCR testing, we welcome the opportunity to bolster the travel industry’s enormous efforts to restore public confidence in international travel.

“We are committed to providing the most cost-effective and accurate test in the market to assist with the normalisation of travel, and so Randox will be opening a number of regional travel centres across Ireland over the coming weeks.”

Dublin Airport Managing Director Vincent Harrison said the health and safety of passengers and staff had been the airport’s key priority during the pandemic and that continued to be the case;

“We continue to operate a range of globally-recognised COVID-19 safety measures for the health and wellbeing of all airport visitors, and with the official opening of the Randox Health Travel Centre at Dublin Airport we can further support our passengers by offering them access to testing facilities onsite at the airport.”

The Randox €99 Express COVID-19 Testing Service is open to all asymptomatic individuals and operates from the Randox Health Travel Centre beside Terminal 2 at Dublin Airport, as well as at a testing facility in Leopardstown Dublin.

In the coming weeks Randox Health Travel Centres will also open in Galway, Limerick and Cork.

Visit booking.randox.ie to book your appointment.

For further information please email info@randoxhealth.com or phone 0800 2545 130.

     

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our COVID-19 Products and Services

    HOME TEST

    ANTIBODY TEST

    TRAVEL CERTIFICATE

    LABORATORY TOOLS


    New Express COVID-19 Testing Service with next day results launched in Dublin

    New Express COVID-19 Testing Service with next day results launched in Dublin

    06 November 2020: New Express COVID-19 Testing Service with next day results launched in Dublin

    A new express COVID-19 testing service has now launched in Ireland, with a rapid next day delivery of results.

    From global diagnostics provider Randox, a laboratory partner in the UK’s National COVID-19 Testing Programme, the service utilises a robust and reliable method of testing known as PCR, the only method recognized and approved for travel testing.

    The PCR testing, which Junior Minister for Transport Transport Hildegarde Naughton described as “the gold standard,” is available in Dublin for pre-travel clearance, or simply for those wanting a COVID-19 test for peace of mind.

    Sophie Boyd, Project Manager for the Randox Express COVID-19 Testing Service, explained;     

     “We appreciate that many people will want a COVID-19 test before travelling home this Christmas, or equally, will want a negative test result to reduce quarantine times and enable them to spend more time with loved ones.

     “PCR testing is currently the only method of COVID-19 testing which is recognised by every country worldwide. Our rapid, accurate and reliable testing service, used already by a range of well-known companies, airlines and elite sporting organisations, will help get plans off to a hassle-free start for travellers and non-travellers alike.”

    The launch of the Randox testing service comes just as Ireland aligns itself with the new EU ‘traffic light’ system to co-ordinate international travel, on Sunday 8th November.

    The Government has agreed that, whilst those arriving from red zones currently have to quarantine for 14 days, this could soon be waived following a negative test result from a COVID-19 test taken five days after arrival in Ireland.

    Sophie continued;

    “Travel requirements during the pandemic continue to evolve, but with the introduction of the EU traffic light system, a common prerequisite will be a negative PCR COVID-19 test prior to travel or to shorten quarantine periods.

    “We have significant capacity in place to implement high volume testing and with our PCR testing service, we look forward to supporting the travel industry’s enormous efforts to restore public confidence in international travel.”

    The Randox Express COVID-19 Testing Service is priced at €99, is open to all asymptomatic individuals and operates from the Clayton Hotel in Dublin.

    Visit booking.randox.ie to book your appointment.

    For further information please email info@randoxhealth.com or phone 0800 2545 130.

      Want to know more about Randox?

      Contact us or visit our homepage to view more.

      Our COVID-19 Products and Services

      HOME TEST

      ANTIBODY TEST

      TRAVEL CERTIFICATE

      LABORATORY TOOLS


      EU Traffic Light System: How to get a COVID-19 PCR test before travelling

      12 October 2020

      EU Traffic Light System: How to get a COVID-19 PCR test before travelling

      EU Traffic Light System: How to get a COVID-19 PCR test before travelling

      As Covid-19 infection rates continue to rise in many parts of the world, an increasing number of countries are asking for a negative PCR test as a means of proof that travellers do not have the Covid-19 virus.

      Whilst not yet a common requirement globally, it is understood that the EU could soon be turning to a Traffic Light System that will require pre-departure testing for individuals departing any of the 15 ‘red list’ countries – which includes the UK and could be extended to include Ireland.

      Whilst there are currently a number of countries across the EU that do not require a negative COVID test for visitors from the UK, the implementation of this co-ordinated approach across the EU will place common requirements on all travellers from the UK, no matter which country they are visiting.

      It could also be used in support of reduced quarantine in those countries which require it.

      So – what is a PCR test?

      PCR stands for Polymerase Chain Reaction and is a method of testing used to detect infectious disease, including COVID-19.

      A PCR test is performed in a laboratory and is indicative of an individual’s COVID status at the time their sample is taken. It does not show previous infection.

      Where can I get a COVID PCR test done?

      PCR tests are available at Randox Health via an in-clinic appointment, or a home sample collection.

      Are home tests accepted as proof of my COVID status?

      It is important to note that many countries do not accept ‘home tests’ as proof of a negative COVID-19 result. Results must show that the test was performed in a certified laboratory.

      Whilst Randox Health offers a home sample collection kit, all our testing is performed using PCR methods in our certified laboratories.

      If the country you are travelling to requires a PCR test result, we’ve got you covered.

      How do I know if I need a COVID PCR test?

      You can check the entry requirements for your destination at gov.uk/foreign-travel-advice

      Requirements are subject to change, so keep checking in the weeks and days leading up to your trip.

      When do I take my sample for testing?

      Your destination country will determine the time frame required for testing. For example, it may state that your sample needs to be taken and tested within 72 hours before departure / arrival. You cannot be swabbed before this time.

      It is best to book / order your test in advance and take it as early as possible within your window, so that you allow for the maximum amount of time to get your test results back.

      How long do I wait for my results?

      Upon receipt of sample at Randox’s laboratories, you will receive your results within 24 hours.

      Our rapid, accurate and reliable COVID-19 testing service will help get your trip off to a hassle-free start, with minimum disruption to your travel plans.

      Visit https://www.randoxhealth.com/covid-travel-certificate/ to order your home sample collection kit or book your clinic appointment.

      For further information please email info@randoxhealth.com or phone 0800 2545 130.

         

        Want to know more about Randox?

        Contact us or visit our homepage to view more.

        Our COVID-19 Products and Services

        HOME TEST

        ANTIBODY TEST

        TRAVEL CERTIFICATE

        LABORATORY TOOLS


        Randox selected to screen travellers to the UAE for Covid-19

        02 September 2020

        Randox selected to screen travellers to the UAE for Covid-19

        Randox Laboratories selected to screen travellers to the UAE for Covid-19, with six sample collection centres across the United Kingdom and Ireland

        Randox Laboratories has been selected by Pure Health, the largest laboratory network in the UAE, to test airline passengers flying into the United Arab Emirates, in accordance with the UAE’s requirement for travellers to prove they are not infected with Covid-19. Pure Health has been appointed by the UAE’s government to launch this pioneering project to promote safe travel.

        “We are delighted to support Pure Health in their efforts to control the Covid-19 pandemic and facilitate safe travels for passengers flying into the UAE,” said David Adamson, Randox Laboratories, Business Development Manager.

        “As one of the largest diagnostic facilities in UK, we are ideally placed to successfully deliver this ambitious initiative, and we are grateful for the trust placed in us.”

        Randox Laboratories has already set up six collection centres across United Kingdom and Ireland. The programme is already up and running in London, Liverpool, Glasgow, Belfast, Antrim and Dublin.

        “The UAE has trusted Pure Health with safeguarding it against any incoming Covid-19 threats, worldwide, this responsibility requires us to ensure we only partner with verified and accredited facilities around the world, thus why we have partnered with Randox Laboratories, to ensure that the screening process is of the highest quality and to ensure an excellent customer service for the travellers.” said Maria El Houari, International Passenger Screening Project Manager at Pure Health.

        The UAE issued regulations that require all travellers flying into the UAE to provide proof of a negative Covid-19 test. Travellers without such a certificate are refused entry into the flight.

        The system is similar to the ESTA process in the United States. The traveller visits screening.purehealth.ae, chooses a testing location, selects a time slot, and completes the test at the agreed time and place. Test results are then transmitted to the UAE authorities, who use the data to cross-check arriving travellers against the border control database.

          For further information please email randoxpr@randox.com

          Want to know more about Randox?

          Contact us or visit our homepage to view more.

          Our COVID-19 Products and Services

          HOME TEST

          ANTIBODY TEST

          TRAVEL CERTIFICATE

          LABORATORY TOOLS


          Dr Peter FitzGerald: “Nothing will ever be the same again.”

          Dr Peter FitzGerald: Nothing will ever be the same again.

          An Interview with Ulster Business Editor John Mulgrew in The Belfast Telegraph, in which Dr FitzGerald speaks to John about developing and helping roll out millions of tests for Covid-19, a forever changed society, the high likelihood of a similar pandemic returning and when a vaccine for the virus could be found.

          Dr Peter FitzGerald’s expertise and opinion has probably never been taken as seriously as it has in the last few months.

          “Nothing will be the same again,” he tells Ulster Business. And, of course, he’s right.

          His firm Randox – based in Antrim – has been on the front line of testing for Covid-19 right across the UK and beyond. And as a result, he’s hired hundreds of new staff and built a £30m testing lab to deal with additional deluge of work resulting from a global pandemic unlike anyone here has ever seen.

          “I think there is a reasonable chance there will be more pandemics, with globalisation and increased population,” he told Ulster Business. “I have no idea how much it will come back again in second wave.

          “We know we have the capacity as a company to respond, and respond well. I suspect the country is going to be better prepared… it’s hard to predict.”

          The medical testing giant’s first involvement with the current coronavirus strain began back in January, before it became an increasingly concerning dinner conversation in homes across Northern Ireland.

          “In late January, research called and were looking at doing a test,” Peter said. “We downloaded the genetic sequence of the virus and spent the next two weeks developing a test. We can do it very quickly, as we already had coronaviruses on chip.

          “It was sent to Public Health England, which took a while to prove it. We then got a contract to test for the NHS… we were doing what we thought was for the national good.”

          The initial deal didn’t include all of the UK, but Randox is now also testing Northern Ireland.

          “We do the testing and we have different analysers that do the testing as well, which we sell to labs across the world.”

          The virus has led to a new complete lab being built (in which Peter is pictured in) to deal with the additional testing. “We decided to accelerate the manufacturing in our Randox Science Park in Antrim,” he says.

          As a result, it has hired around 200 staff in the space of six to eight weeks to deal with the surge.

          “Because we had closely related strains of the virus, it was wasn’t so difficult to modify our tests to allow for slightly different variations… once we got the contract we soon realised that we didn’t have enough lab space to deal with the ramp up.

          “We then decided to be 33,000 sq ft of new lab space, and it was needed in three weeks. We got that done – work was 24 hours a day, and seven days a week. It’s now operating well. That has been very important in the process.”

          Randox had a workforce of around 1,450 worldwide before the coronavirus crisis began, but has since taken on around 280 additional staff for a range of roles, partly in ramping up demand for the additional testing.

          “A lot were being taken on a temporary basis but many will be permanent. We are not sure of the final numbers, but well over 100.” Those roles include scientists, manufacturers, and engineers.

          “Nothing will be the same again,” Peter says. “What it has done is heightened the importance of testing. People sometimes don’t know what we do here at Randox… but people now realise.

          “In the end, it’s a good thing. We are advocates of testing. It identities disease before symptoms occur and can save lives in many occasions. It saves lives and saves costs. It fits in with what we have been trying to do for years… as far as we are concerned, it’s the silver lining.

          “We have customers worldwide and other products kept going. We moved around 100 scientists into Covid-related things and then they have gone back to normal jobs as we bring in new people.

          “Some of our R&D projects have changed, new systems and new analysers allow for efficient and accurate testing.”

          Peter says that just a small element of the business has seen a decrease amid the crisis, while other areas around Covid-19 have grown. “Only a small element of core business decreased. But our Covid and other genetic products have increased… overall sales will be up and by end of year normal business up as well.”

          As a result of the latest expansion and growth across the business, generally speaking, Peter says the workforce looks set to climb to 1,650, with around 500-600 based at its main headquarters, just outside Antrim.

          Peter’s also keen to reiterate the importance of Northern Ireland and its people to Randox. “This is our home base. It’s where we do our primary R&D and manufacturing. We also have a facility in Donegal.”

          And, could all of this happen again soon, with a further outbreak or a similarly devastating strain or pandemic?

          “(We are) more prepared and our technology is getting more accepted through bio chips. Early detection is a very important next stage. You don’t want people who have a cough or fever to think they have Covid all the time. That is where testing comes in and that differentiates.”

          Peter says the next stop forward in a bid to address similar future incidents it also understanding how our immune systems work – better.
          “The other major step forward in many ways is understanding the immune system better. How to better respond to infection. This will be very important.

          “Some people are susceptible, and this could be genetic. (It’s about) working on certain genes in those who may have a bad attack. It will prepare humans better, the body’s defence, dealing with it as well.

          “I have a deficiency in a particular gene which means I’m more susceptible to respiratory (conditions) but the spin-off of the gene means I’m less susceptible to certain cancers. This is the issue – it is so complex. One could be a strength and one moment, a weakness.”

          And as for the formulation of a proven vaccine, Peter says: “I would say it would be well into next year.”

            For further information please email randoxpr@randox.com

            Photo Credit Elaine Hill

            Want to know more about Randox?

            Contact us or visit our homepage to view more.

            Our Randox Products and Services

            REAGENTS

            RX SERIES

            ACUSERA

            BIOCHIP


            COVID-19 Testing Service Testimonial: The Irish Football Association

            News       About Us       COVID-19

             

            25 July 2020

            COVID-19 Testing Service Testimonial: The Irish Football Association

            As we move towards a new ‘normal’ and sporting organisations begin the process of restarting their games, many teams will be wondering how to ensure a safe and reassuring training environment for their players and their staff.

            Thanks to our COVID-19 testing service, The Irish Football Association was able to facilitate a timely and efficient return to play by confirming their players as ‘COVID-safe.’

            Our ‘Back to Business’ programme has enabled the IFA to demonstrate their commitment to their players, their staff, and their fans, as well as get back to business by ensuring the highest level of safety.

            Corinne Lannie, Risk Manager at the Irish Football Association, commented;

            “The test kits were very straightforward to use.  The instructions were clear as was the YouTube guidance video. The recording onto the Randox system was easy and the speed of results was exceptional.

            “The support provided by Paul (Randox Business Development Executive) was amazing – he was extremely helpful and supportive and really went above and beyond.”

            At Randox, we offer two types of testing;

            PCR (diagnostic) testing, and antibody testing, which can give an indication that an individual has been previously infected with COVID-19.

            Sample collection services are available.

            David Hallendorff, Business Relations Manager at Randox Health commented;

            “Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.

            “To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.

            “It is great to see so many companies putting the health of their staff as a priority and taking a proactive approach to testing.

            To find out more about our Back to Business COVID-19 Testing Service, please email info@randoxhealth.com or phone 0800 2545 130

             

             

            Want to find out more?

            Click one of the links below.

            COVID-19 Products and Services

            HOME TEST

            ANTIBODY TEST

            TESTING SERVICE

            LABORATORY TOOLS


            The Importance of Diagnostics

            What We Do       Our Team       Our History

            Healthcare Diagnostics: The Future of a Vital Industry

            Randox was established in 1982 to address the need for accurate and readily available diagnostic tests to improve patient diagnosis. Around 70% of all medical decisions are based on laboratory results, and so, not surprisingly, we believe that earlier, more accurate and more accessible diagnostics are the key to improving global health and saving lives.

            And yet, until now, in spite of their contribution to clinical decision making, and the important role they play in patient outcomes, diagnostic tests have only accounted for 2% of the UK’s national health budget.

            But things are changing. What was once a little-understood industry, working diligently behind-the-scenes, has quickly become an area of interest and relevance to just about everybody, given the key role the sector has played during the COVID-19 outbreak.

            Whilst regrettable that it has taken a pandemic to bring the health diagnostics sector into focus, it is a positive step forward for healthcare that the huge national and international scope of our sector is now rightly acknowledged.

            Click the links below to hear from a range of clinicians, pathologists and public officials on the importance of diagnostics, and from our customers on their experience of Randox testing technologies.

            • Key Opinion Leaders
            • Clinical Customers
            • COVID-19 Testing Service Customers
            • Case Studies
            • Randox in the media
            • Diagnostics in the media

            UK Prime Minister Boris Johnson

            22 September 2020

            Secretary of State for Health Matt Hancock

            21 September 2020

            Mayor of Antrim and Newtownabbey Alderman John Smyth

            26 June 2020

            Secretary of State for Health Matt Hancock

            25 June 2020

            Minister for Innovation James Bethell

            25 June 2020

            Minister for Innovation James Bethell

            11 June 2020

            Secretary of State for Health Matt Hancock

            23 April 2020

            UK Research and Innovation Chief Executive Prof Sir Mark Walport

            29 January 2019

            Minister of State for Northern Ireland John Penrose

            07 December 2018

            Chair Life Sciences Industrial Strategy Sir John Bell

            22 February 2018

            Quality Control Technologies Specialist Sten Westgard

            07 October 2016

            Tánaiste and Fine Gael Leader Leo Varadkar

            18 March 2015

            Adrian Cudmore NHS

            Dr Caje Moniz NHS

            Dr Rosa Sierra Amor

            Dr Bianca Thakkar

            Dr Anil Shah

            Dr Pragati Desai

            Dr Pramod Ingale

            Dr Rajeev Mehta

            Dr Simple Bhuptani

            Dr SM Patel

            Dr Trupti Patel

            Dr A Vahed Mulla

            Randox Health client travelling with TUI

            17 October 2020

            Randox Health client travelling from Glasgow

            08 September 2020

            Pure Health Passenger Screening Manager Maria El Houari

            02 September 2020

            Irish Football Association Risk Manager Corinne Lannie

            25 July 2020

            Liverpool Chamber of Commerce CEO Paul Cherpeau

            23 July 2020

            NSCB Medical College

            07 July 2020

            Norbrook Laboratories

            27 May 2020

            Royal Free Hospital London

            16 July 2017

            LUKMEF Cameroon

            03 October 2016

            Biomédica de Referencia

            18 March 2015

            Daily Mirror/Belfast Live

            24 November 2020

            The Sunday Times

            01 March 2020

            Mail Online

            21 March 2019

            GOV.UK

            04 January 2019

            The Sun

            05 July 2012

            Mail Online

            09 August 2014

            The Telegraph

            12 August 2016

            The Daily Telegraph

            24 June 2020

            The Times

            22 January 2018

            The Irish Times

            23 December 2016

            Want to know more?

            Contact us or read the latest news on Randox.

            What We Do

            Our History

            Our Accreditations


            Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

            News       About Us       COVID-19

             

            29 June 2020

            Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

            Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

            In a recent Opinion Piece in The Daily Telegraph, our Managing Director Dr Peter FitzGerald stressed the value of diagnostics, the important role it plays in public health, and the contribution it has made specifically during the COVID-19 pandemic.

            Whilst regrettable that it has taken a pandemic to bring the health diagnostics sector into focus, it is a positive step forward for healthcare that the huge national and international scope of our sector is now rightly acknowledged.

            Indeed, Dr FitzGerald’s commentary was acknowledged by both the Secretary of State for Health, Matt Hancock, and the Minister for Innovation, Jim Bethell.

            The Secretary of State noted that “Randox have played a vital role in building our global-scale diagnostics capacity.”

              It is clear that the diagnostics industry, inclusive of the work Randox has done in the field, has had a positive impact in the fight against COVID-19. We know that testing at scale is the most effective way to both save lives, and ensure a timely return to a more normal society.

              We are very proud of our staff, for their ongoing support, and for their commitment to the work that we do, which is making a real and positive difference.

              You can read Dr FitzGerald’s full Opinion Piece for The Daily Telegraph, on our own website, by clicking here.

              For further information please contact randoxpr@randox.com or phone 028 9442 2413

              Want to know more about Randox?

              Contact us or visit our homepage to view more.

              Our Randox Products and Services

              REAGENTS

              RX SERIES

              ACUSERA

              BIOCHIP


              COVID-19 has shown UK leadership on diagnostics; we can now become a world leader

              News       About Us       COVID-19

               

              25 June 2020

              COVID-19 has shown UK leadership on diagnostics

              COVID-19 has shown UK leadership on diagnostics; we can now become a world leader

              An Opinion Piece by Dr Peter FitzGerald, Managing Director of Randox Laboratories, in The Daily Telegraph

              When I founded Randox Laboratories in 1982 in Antrim, Northern Ireland, I could not have envisaged that today we would be manufacturing more clinical diagnostic products than any other company in the UK. Whilst I am incredibly proud that Randox is taking a leading role in the national Covid-19 testing effort, it is deeply regrettable that it has taken this pandemic to bring the UK’s health diagnostics sector into focus.

              The pandemic represents the biggest diagnostics and health infrastructure challenge of modern times.  It has forced and necessitated a herculean collaborative effort from Government, the NHS and the private sector. This partnership has delivered a new trust and information sharing network which bodes well for the future.

              Ministers now know what we can do and rightly acknowledge the huge national and international scope of our sector and for global UK leadership and new skilled jobs.  The Government is right to highlight and reflect that too many of these critical sectors and supplies have been allowed to be offshored in recent years. This has consequently had implications for patient care and the support available for health workers.

              In March, the World Health Organisation’s Director General, Tedros Adhanom Ghebreyesus, said that he had a simple message to countries on how to deal with the COVID-19 outbreak that was sweeping the globe, this message was ‘Test, test, test.’ In the UK, mass testing was, at that time, simply not possible. Indeed, the Health Secretary, Matthew Hancock, acknowledged  that it was the lack of a significant domestic diagnostic industry that had impeded the Government’s initial efforts on testing, which is why we were behind Germany and other states.  He was right and much has already been done to re-shore capacity and re-set this policy alongside understanding the importance for future British sector leadership.

              Going forward, we can and must deliver a new and much tighter partnership between the NHS and private sector across diagnostics and preventative healthcare. Improved communication, co-operation and partnerships will grow British sector expertise, jobs and skills.  The potential for British leadership and success here is huge.

              Earlier this month, I had the pleasure of welcoming Northern Ireland Secretary, Brandon Lewis MP to see our new £30m specialist Covid-19 testing hub at the Randox Science Park in Northern Ireland.  This investment will create 200 new science, engineering and manufacturing jobs at the facility on top of our existing workforce. It was fast-tracked over the space of four weeks and is the first step in a wider diagnostics investment programme as part of Randox’s efforts to enhance our national Covid testing capacity.

              A wider appreciation of the value and resource support for diagnostics testing and preventative health policy is now overdue and timely especially when you consider that seventy per cent of all medical decisions are based on the results of lab tests.  This testing must now account for more than the two per cent of the national healthcare budget.   Alongside our major focus on R&D, our scientists work on pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease. With around twenty five percent of turnover reinvested in R&D, Randox has more new tests in development than any other diagnostic company.  Our products are used across hospitals and veterinary laboratories, food testing, forensic toxicology and life sciences.

              Randox labs have spent over £305 million researching the thousands of biomarkers present in our bodies and have identified the gold standard in testing. Our patented Biochip Array Technology has revolutionized the diagnostics industry by offering a unique testing platform which allows multiple tests to be carried out from a single patient sample. On Covid, we have been able to include two tests on the same biochip; one specific and one confirmatory as recommended by the World Health Organisation.

              The ambition and determination to build a world-beating British diagnostics sector is overdue and right.  It offers so many advantages ranging from a healthier and happier population which lives longer to more skilled jobs in a sector which works hand in glove with our world beating academia and NHS.  The pandemic has rightly brought the UK’s diagnostics capability into sharp focus, and it is paramount that when we move to a post-Covid world, we take what we have learned from this crisis and build a self-reliant sector fit for the future.

                For further information please email randoxpr@randox.com

                 

                Want to know more about Randox?

                Contact us or visit our homepage to view more.

                Our Randox Products and Services

                REAGENTS

                RX SERIES

                ACUSERA

                BIOCHIP


                FAQs for Media

                Frequently Asked Media Questions

                Randox have almost 40 years of experience as a primary manufacturer in the IVD (in vitro diagnostics) industry. Last year we manufactured over 3 billion tests and exported to 145 countries. Randox are an ISO 13485 accredited manufacturer of in-vitro diagnostic medical devices, are a provider of a global laboratory accreditation scheme (RIQAS) accredited to ISO 17043, and run a number of ISO 17025 accredited laboratories. As an exporter to 145 countries and a manufacturer to other diagnostic companies we undergo multiple external audits each year, in order to remain engaged with our global markets.

                At the time of the emergence of the COVID-19 threat, Randox had already developed seven CE marked assays for a range of viruses, including a number of other coronaviruses.

                Upon identifying the latest strain of coronavirus as a significant global threat, Randox was able to harness our R&D capability, and some 40 years’ in diagnostics, including viral tests, to develop an effective COVID-19 assay with the same rigorous validation processes that we applied to all our other assays.

                The Randox COVID-19 test underwent evaluation within, and was accepted by, Public Health England.

                In its evaluation of the Randox COVID-19 test, Public Health England’s report noted that the assay correctly identified all positive and negative samples without exception.

                 

                As one of the UK’s major life sciences companies, providing diagnostic capabilities both within the UK and globally for almost 40 years, Randox has maintained regular contact with senior officials directly responsible for Life Sciences in the UK, particularly in the fields of diagnostic capability and innovation. We had developed our COVID-19 testing capability by mid-February 2020, and notified officials as such.

                Over a number of weeks, we worked collaboratively with government to determine how best we might be able to support the national testing programme.

                Our contribution to this programme, which was announced on 27th March, was the culmination of significant engagement, from the identification of the threat, until that date.

                The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test. When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.

                Randox are providing high volume testing within our laboratories.

                It should be noted that Randox is only one partner within a multi-partner, national testing programme being run and coordinated by the Department of Health and Social Care.

                In order for the testing programme to work efficiently, all partners work to ensure effective processes at each stage of the testing journey – from testing kit distribution and sample collection to transportation and delivery, and finally, the testing of the sample.

                For our part, we are focused diligently on processing all tests in a timely manner after receipt of sample at our laboratory.

                It is our priority to ensure that we support the national effort to fight COVID-19, by testing at scale, as we know that this is the most effective way to save lives and promote a timely return to a more normal society.

                Our COVID-19 testing currently (as at June 2020) accounts for up to 17% of the national testing programme.

                PHE managed the validation process for each of England, Wales, Scotland and Northern Ireland.

                We understand that the national plan for COVID-19 testing is exactly that, a national plan, inclusive of Northern Ireland. The planning for the national distribution of test kits is being managed by the various statutory agencies however Randox made the case that tests should be made available locally.

                Following that engagement, Randox tests were made directly available within Northern Ireland, and sent, for example, to the drive-through test centre at the SSE arena.

                Randox will continue to support Northern Ireland within the UK national plan.

                The Randox COVID-19 test is a molecular-based test which looks for SARS-CoV-2 (the virus that causes COVID-19) within the body.  PCR (Polyamerase Chain Reaction) techniques are used to detect viral RNA (ribonucleic acid) contained inside the SARS-CoV-2 virus.

                The platform used for testing is Randox’s proprietary Biochip Technology, which allows multiple tests to be carried out simultaneously.

                The COVID-19 Biochip conducts two tests – one specific and one confirmatory – as recommended by the World Health Organisation and the Centres for Disease Control and Prevention.

                The majority of results are reported within 24 hours of receipt of sample at our laboratories.

                There will always be challenges within the first few months of an unprecedented programme facing an unprecedented threat and the associated global supply chain issues affecting all countries and organisations.

                We are successfully overcoming these issues, ramping up our testing capacity, and moving forward positively with all stakeholders. We remain committed to the provision of optimal support to the national testing programme and the wider effort to fight COVID-19.

                The Health Secretary, Matthew Hancock, acknowledged that it was the lack of a significant domestic diagnostic industry that had impeded the Government’s initial efforts on testing, which helps explain the variation between the UK and other countries.

                Read an Opinion Piece from our Managing Director, Dr Peter FitzGerald, on the Telegraph Online, by clicking here.

                In support of our role within the national testing programme we have invested £30m in a new COVID-19 testing laboratory at the Randox Science Park in Northern Ireland.

                We have hired almost 300 new staff, and are recruiting for an additional 200 across science, engineering and manufacturing.

                Find out more here.

                As we continue to ramp up our testing capabilities, and work alongside the government to offer this testing to an increasing list of individuals, we also recognize a demand from a range of businesses who wish to adopt our innovative COVID-19 testing technologies to address their own particular testing requirements, without impacting on the public health need.

                The Randox COVID-19 test is available to purchase as part of our ‘Get Back to Business’ COVID-19 testing service, for staff screening.

                Since developing our COVID-19 assay, we have had various discussions with interested parties from countries such as China, Italy, Japan, Spain and of course the UK, on how to utilise the test to help their country’s response to the coronavirus outbreak.

                Yes, Randox can conduct antibody testing.

                Find out more here.

                On 7th August we took the decision to recall Covid-19 sample collection kits, following the identification of incomplete EC certification.

                On 15th July DHSC placed these kits on hold due to the absence of swab certification from an external supplier. To date, Randox have not been provided with evidence to satisfactorily support the CE marking for these swabs.

                So, noting the lack of CE certification by the supplier and that some kits remain in the field at this time Randox, as a regulatory measure, initiated the recall of those kits used within the National Testing Programme.

                Randox Laboratories will continue to provide high volume Covid-19 testing to the National Testing Programme from their laboratories, based on sample collection kits from other providers.

                DHSC have stated the risk to safety is low and test results from Randox kits are not affected.

                The decision to recall Randox sample collection kits within the UK National Test and Trace Programme does not apply to our private business which uses a different supplier of swabs.

                Randox private customers or kits are not affected.

                For COVID-19 press enquiries please email randox@newcenturymedia.co.uk

                Want to know more?

                Contact us or visit our news page.

                Newspage

                What We Do

                Contact Us


                Request a meeting
                ×
                Make an Enquiry - RX series
                ×
                Make an Enquiry - Reagents
                ×
                Kit Insert Request - Reagents
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                Kit Insert Request - Reagents
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                Make an Enquiry - Reagents
                ×
                Make an Enquiry - Quality Control
                ×
                Make an Enquiry - RIQAS
                ×
                Make an Enquiry - RIQAS
                ×
                Make an Enquiry - Quality Control
                ×
                Make an Enquiry
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                Make an Enquiry - Biochip
                • This field is for validation purposes and should be left unchanged.
                ×
                Make an Enquiry - Molecular
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                • This field is for validation purposes and should be left unchanged.
                ×
                Make an Enquiry - Future Diagnostics
                ×
                Make an Enquiry - RX series (Product)
                ×
                Make an Enquiry - Quality Control
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                Make an Enquiry - RIQAS
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                Make an Enquiry - Reagents
                • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                Por favor, introduzca sus datos para ver nuestro último seminario
                ×
                Wyślij zapytanie
                • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
                ×
                Wyślij zapytanie
                • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
                ×
                Wyślij zapytanie
                • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
                ×
                Wyślij zapytanie
                  Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
                ×
                귀하의 문의 사항 제출
                  Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                ×
                귀하의 문의 사항 제출
                ×
                귀하의 문의 사항 제출
                ×
                귀하의 문의 사항 제출
                ×
                Downloads
                ×
                Contact

                <p>

                  Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
                </p>

                ×
                Enquire Now - Coronavirus Testing